Ensysce Biosciences, Inc.
General ticker "ENSC" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $5.7M (TTM average)
Ensysce Biosciences, Inc. does not follow the US Stock Market performance with the rate: -3.4%.
Estimated limits based on current volatility of 5.5%: low 1.52$, high 1.70$
Factors to consider:
- Total employees count: 7 (0.0%) as of 2024
- Top business risk factors: Going concern, Profitability concerns, Labor/talent shortage/retention, Manufacturing risks, Intellectual property risks
- Current price 60.9% below estimated low
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [4.17$, 15.97$]
- 2025-12-31 to 2026-12-31 estimated range: [2.64$, 10.94$]
Financial Metrics affecting the ENSC estimates:
- Negative: with PPE of -0.6 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -51.29 <= 0.33
- Negative: negative Industry operating cash flow (median)
- Negative: negative Net income
- Positive: Investing cash flow per share per price, % of 0 > -0.66
- Negative: Interest expense per share per price, % of 8.82 > 3.41
- Positive: Industry inventory ratio change (median), % of 0 <= 0
Short-term ENSC quotes
Long-term ENSC plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 |
|---|---|---|
| Operating Revenue | $2.23MM | $5.21MM |
| Operating Expenses | $12.95MM | $11.94MM |
| Operating Income | $-10.72MM | $-6.73MM |
| Non-Operating Income | $-0.20MM | $-1.26MM |
| Interest Expense | $0.35MM | $1.29MM |
| R&D Expense | $7.59MM | $7.22MM |
| Income(Loss) | $-10.92MM | $-7.99MM |
| Profit(Loss)* | $-10.61MM | $-7.99MM |
| Stockholders Equity | $-0.32MM | $3.71MM |
| Assets | $2.71MM | $5.60MM |
| Operating Cash Flow | $-10.78MM | $-7.50MM |
| Financing Cash Flow | $8.76MM | $9.88MM |
| Earnings Per Share** | $-4.69 | $-4.57 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.